Brain+ A/S is engaged in the developing of medical software to detect and treat the cognitive symptoms of dementia and the most common cause of dementia, namely Alzheimer's disease. It is involved in digital therapeutics that can be used independently or in combination with traditional medications, devices, and other therapies to optimize patient care and health outcomes. The company was founded by Kim Baden-Kristensen, Ulrik Ditlev Eriksen, and Rasmus Højengaard on April 17, 2012 and is headquartered in Copenhagen, Denmark.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company